What the GLOBE Model Final Rule Tests: A Plain Reading of the Federal Register Summary

On October 2, 2026, the Centers for Medicare & Medicaid Services (CMS), part of the Department of Health and Human Services, published a final rule in the Federal Register that establishes the Global Benchmark for Efficient Drug Pricing Model, abbreviated as the GLOBE Model ^[1]. The document number is 2026-20281 ^[1]. This explainer addresses two related questions: what the GLOBE Model sets out to test, and what the published summary leaves open ^[1].

What the rule establishes

The rule is a final rule, and it implements the GLOBE Model as a new Medicare payment model ^[1]. CMS describes the model as mandatory ^[1]. The legal basis named in the summary is section 1115A of the Social Security Act ^[1]. According to the summary, the model uses an alternative method for calculating Medicare Part B drug inflation rebate amounts ^[1].

The question the model is designed to answer

The summary frames the model as a test, and its single sentence on the subject contains four parts ^[1]:

• The intervention: an alternative method for calculating Medicare Part B drug inflation rebate amounts ^[1].
• The scope: certain separately payable Medicare Part B drugs and biological products ^[1].
• The outcomes of interest: costs for Original Medicare beneficiaries and costs for the Medicare program ^[1].
• The condition: quality of care is preserved ^[1].

Taken together, the model asks whether changing the rebate calculation for a defined set of Part B products reduces costs for beneficiaries and for Medicare while preserving quality of care ^[1]. The summary uses the phrase "will test whether" ^[1]. It does not claim that the alternative method reduces costs; it states only that the model will test whether it does ^[1]. A statement that the GLOBE Model saves money for patients or for Medicare would therefore go beyond what the published summary supports ^[1].

Terms used in the summary

Original Medicare (OM) is the rule's term for the beneficiary population whose costs are named as an outcome ^[1]. The rule states that OM has the same meaning as Medicare fee-for-service and the traditional Medicare program ^[1]. The beneficiary cost outcome named in the summary is therefore framed around the fee-for-service program ^[1].

The summary names two product classes, Part B drugs and biological products, and as written the scope covers both ^[1].

The words "certain" and "separately payable" narrow which Part B products are in scope ^[1]. The summary does not define either qualifier and does not list the products ^[1].

The inflation rebate amount is the quantity the model recalculates ^[1]. The summary refers to Medicare Part B drug inflation rebate amounts and says the model uses an alternative method to calculate them, but it does not describe either the existing method or the alternative one ^[1].

What the summary does not settle

Several details are not stated in the summary itself ^[1]:

• The specific drugs and biological products in scope ^[1].
• How the alternative calculation method works, including what the "global benchmark" in the model's name refers to ^[1].
• The start date, the duration and any geographic limits of the model ^[1].
• Which entities must take part under a model the summary calls mandatory ^[1].
• How quality of care will be measured to judge whether it was preserved ^[1].

A practical way to read the full rule

The four elements in the summary (intervention, scope, outcomes and condition) can serve as headings for organizing a review of the full rule ^[1]. Under those headings, the matching questions are which products are in scope, how the alternative calculation method works, how beneficiary and program costs are measured, and how quality of care is assessed ^[1].

The document number, 2026-20281, together with the publication date of October 2, 2026, identifies the specific version of the rule that the summary describes ^[1].

The definition of Original Medicare is worth carrying into any internal analysis ^[1]. Because the rule equates OM with Medicare fee-for-service and traditional Medicare, the beneficiary population named in the summary is the fee-for-service population ^[1].

Limitations

This explainer relies only on the Federal Register summary of the final rule ^[1]. It does not draw on the full regulatory text, the preamble or any impact analysis, and it does not report whether the full text addresses the open points listed above ^[1]. Definitions are therefore limited to what the summary states, and the only term it defines explicitly is Original Medicare ^[1]. The summary describes the model prospectively, as something that will be tested, so this source contains no evaluation findings on costs or quality of care ^[1].